Re: Interim phase-2 data on VX-135 + Daclatasvir It simply looks like VX-135 doesn't have what it takes for a component in a combo to compete with what GILD and ABBV have.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.